Skip to main content
SOLARA ACTIVE PHARMA SCIENCES LIMITED logo

SOLARA ACTIVE PHARMA SCIENCES LIMITED — Investor Relations & Filings

Ticker · SOLARA ISIN · INE624Z01016 LEI · 3358008SUKH3YE2F7F81 BSE.NS Manufacturing
Open in API
Filings indexed 680 across all filing types
Latest filing 2026-05-16 Report Publication Anno…
Country IN India
Listing BSE.NS SOLARA

About SOLARA ACTIVE PHARMA SCIENCES LIMITED

https://www.solara.co.in/

Solara Active Pharma Sciences Limited is a customer-centric organization specializing in the development and manufacturing of active pharmaceutical ingredients (APIs). The company offers a diverse portfolio of high-quality products across therapeutic categories such as pain management, central nervous system, and anti-infectives. It operates several manufacturing sites and research centers that comply with global regulatory standards, including the USFDA and EUGMP. Beyond its commercial API catalog, the company provides comprehensive contract development and manufacturing organization (CDMO) services, assisting partners from the initial research phase to large-scale production. Known for its significant production capacity in key molecules like Ibuprofen, the company focuses on delivering complex and niche APIs to global markets through advanced technical expertise and a commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Report Publication Announcement Classification · 91% confidence The document is a cover letter to India’s stock exchanges notifying them that the company’s audited annual and unaudited quarterly financial results have been published in newspapers and made available on the website. It contains no actual financial data—only a notice that the extracts are attached/published—so under the “Menu vs. Meal” rule this is an announcement of report publication, not the report itself. This matches our definition for Report Publication Announcement (RPA).
2026-05-16 English
Copy of newspaper publication with respect to financial results for the quarter and year ended March 31, 2026
Report Publication Announcement Classification · 87% confidence The document is a formal letter dated May 16, 2026 from Solara Active Pharma Sciences to the BSE and NSE. It notifies the exchanges that copies of the newspaper advertisement containing the audited annual results and unaudited quarterly results have been published and enclosed. It does not itself present detailed financial statements but announces that the newspaper extract is published and available. This fits the definition of a Report Publication Announcement (RPA): an announcement regarding the publication of company reports.
2026-05-16 English
Analysts/Institutional Investor Meet/Con. Call Updates
Report Publication Announcement Classification · 87% confidence The document is a brief notice to stock exchanges that the audio recording of the Q4 FY26 earnings call has been uploaded to the company’s website, without containing any actual financial data or transcript. It announces the publication of a report (the call audio) rather than providing the report itself, fitting the definition of a Report Publication Announcement (RPA).
2026-05-15 English
Solara Active Pharma Sciences Limited has intimated the Exchange about the Audio Recording of the Q4 FY26 Earnings Call held on May 15, 2026, at 15.00 IST.
Report Publication Announcement Classification · 85% confidence The document is a short notification to stock exchanges under SEBI regulations stating that the audio recording of the Q4 FY26 earnings call has been uploaded to the company website. It does not include any financial data or the transcript itself, but merely announces the availability of the audio report. This fits the definition of a Report Publication Announcement (RPA).
2026-05-15 English
Monitoring Agency Report for the quarter ended March 31, 2026
Regulatory Filings Classification · 90% confidence The document is a statutory compliance filing under SEBI (LODR) Reg. 32(6) and SEBI ICDR Reg. 82(4), providing the full Monitoring Agency Report on utilization of proceeds from a Rights Issue for the quarter ended 31 Mar 2026. It is neither a full financial report (10-K/IR), nor a simple earnings release or management presentation. It is a regulatory compliance report sent to the exchanges, falling under “General regulatory announcements / compliance documents” – i.e., the RNS category.
2026-05-15 English
Monitoring Agency Report
Regulatory Filings Classification · 85% confidence The document is a Monitoring Agency Report issued by Crisil Ratings Limited for the quarter ended March 31, 2026, pursuant to SEBI Listing Obligations and SEBI ICDR Regulations concerning a Rights Issue. It contains detailed tables on utilisation of proceeds and confirmations, but it is neither an earnings release, annual/interim report, nor an audit report. There is no bespoke category for monitoring agency reports, so it falls under the catch-all Regulatory Filings (RNS) category.
2026-05-15 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.